Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled Trail

Phase 4

• Conditions: Acute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failure; Acute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarker

• Registration Number: TCTR20221003002
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-03
• Study Completion: 2023-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

1. acute decompensated heart failure
1.1 dyspena at rest or dyspnea on minimal exertion
1.2 signs of pulmonary congestion
1.3 NT- proBNP more than 1600 pg/ml or more than 2000 pg/ml in atrial fibrillation patients
2. No vasodilator intravenous within 6 hours
3. No vasopressor and inotropic drug intravenous within 6 hours

Exclusion Criteria

1. Type 1 diabetes
2. History of diabetic ketosis or ketosis
3. GFR (CKD-EPI) < 30 ml/min/1.73 square meter
4. History of prior SGLT2 inhibitor
5. Systolic blood pressure < 100 mmHg
6. Cardiogenic shock
7. History of percutaneous coronary intervention within 30 days before enrollment or planned for percutaneous coronary intervention
8. Immunosuppressive agent use
9. Acidemia with pH < 7.2
10. Sepsis or septic shock
11. Liver failure
12. Pregnancy or breast feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AKI 0,1,2,3,7,14,28 days after enrollment Creatinine,Change in [TIMP-2] x [IGFBP7] 0, 7, 28 days after enrollment Nephrocheck

Secondary Outcome Measures

Name	Time	Method
Change in GFR 0,1,2,3,7,14,28 days after enrollment CKD-EPI,Length of stay 28 days after enrollment Researcher reports from medical data,Urine output 1, 2, 3 days after enrollment Measurement of urine output per day,Adverse event 28 days after enrollment Patients and researcher report adverse event ,28-day mortality 28 days after enrollment Resercher reports from medical record